Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Foscavir

(Foscarnet sodium)

ApprovedSmall molecule

CClinigen, Inc.

Foscarnet sodium is used to treat serious viral infections, particularly cytomegalovirus (CMV) infections in people with weakened immune systems, and herpes simplex virus infections that don't respond to other treatments.[2] Foscavir is currently approved and in use across 6 indications[4].[1]

Foscavir is one of 93 small molecule programs targeting Cytomegalovirus Retinitis. It is currently in Approved.

6

Indications

24

Total Trials

1

Active Trials

92

Competitors

22

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cytomegalovirus RetinitisUnknown

Inborn Error of ImmunityUnknown

PneumoniaUnknown

TreatmentCompleted

Herpes ZosterCompleted

Cytomegalovirus RetinitisPreclinical

Unknown

Inborn Error of ImmunityPreclinical

Unknown

PneumoniaPreclinical

Unknown

TreatmentPreclinical

Completed

Herpes ZosterApproved

Completed

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Foscavir

CClinigen, Inc.

Biltricide

Alfenta

Jazz Pharmaceuticals

Niclocide

Minipress

Theo-Dur

Hivid

CConrado Roberto Hoffmann Filho

Nerlynx

PPuma Biotechnology, Inc.

Clomid

Aurlumyn

BBTG International Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Active, not recruiting

Hematopoietic/lymphoid Cancer

NCT01199562

Clinical

Trials by Indication[1]

Treatment6 trials

A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000856

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000970·30 enrolled

CMV Retinitis Retreatment Trial

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000766·300 enrolled

Show 3 more trials

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001061·167 enrolled

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000985·26 enrolled

An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

Completed·AAstra USA·N/A·NCT00002039

Immunodeficiency3 trials

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000726·53 enrolled

An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Completed·AAstra USA·N/A·NCT00002021

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Completed·AAstra USA·N/A·NCT00002272

Cytomegalovirus (CMV)3 trials

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

Unknown status·AAstra USA·N/A·NCT00002301

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Completed·AAstra USA·N/A·NCT00002432

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000697

Scar2 trials

The Effect of Stomach Acid on Foscarnet

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000964·6 enrolled

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000729·10 enrolled

Cytomegalovirus Infection1 trial

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Unknown status·UUniversity Hospital Birmingham·Phase 2·NCT00986557·78 enrolled

9 more indications

HIV infection1 trial

A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001002·12 enrolled

Complication1 trial

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000665·240 enrolled

Herpes Zoster1 trial

Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster

Completed·CCttq·Phase 4·NCT02151240·94 enrolled

Intravenous1 trial

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

Completed·AAstra USA·Phase 4·NCT00002125·112 enrolled

Gastrointestinal1 trial

Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease

Completed·AAstra USA·Phase 3·NCT00002145·145 enrolled

Myelosuppression1 trial

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000691·156 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

Completed·AAstra USA·Phase 4·NCT00002146·12 enrolled

Herpes Simplex Virus1 trial

The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

Completed·AAstra USA·Phase 1·NCT00002144·12 enrolled

Hematopoietic/Lymphoid Cancer1 trial

Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function

Active, not recruiting·CCity of Hope Medical Center··NCT01199562·153 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 27, 1991

FOSCAVIR

NDA NDA020068

Sep 27, 1991

FOSCAVIR

NDA NDA020068

Jun 16, 1995

FOSCAVIR

NDA NDA020068

Nov 17, 1995

FOSCAVIR

NDA NDA020068

Dec 12, 1995

FOSCAVIR

NDA NDA020068

Jan 3, 1997

FOSCAVIR

NDA NDA020068

Jan 24, 1997

FOSCAVIR

NDA NDA020068

Jan 24, 1997

FOSCAVIR

NDA NDA020068

Jan 24, 1997

FOSCAVIR

NDA NDA020068

Mar 31, 1997

FOSCAVIR

NDA NDA020068

Nov 16, 1998

FOSCAVIR

NDA NDA020068

Jun 13, 2000

FOSCAVIR

NDA NDA020068

Jun 13, 2000

FOSCAVIR

NDA NDA020068

May 15, 2006

FOSCAVIR

NDA NDA020068

Nov 27, 2007

FOSCAVIR

NDA NDA020068

Feb 10, 2012

FOSCAVIR

NDA NDA020068

Jun 10, 2014

FOSCAVIR

NDA NDA020068

Nov 7, 2014

FOSCAVIR

NDA NDA020068

May 29, 2015

FOSCAVIR

NDA NDA020068

Nov 10, 2016

FOSCAVIR

NDA NDA020068

Feb 24, 2017

FOSCAVIR

NDA NDA020068

Oct 28, 2020

FOSCAVIR

NDA NDA020068

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Foscarnet sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Foscavir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Foscarnet sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Foscarnet sodium. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020068). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Clinigen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Herpesvirus 1 DNA Polymerase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CClinigen, Inc.

Related News